Hap Trading, LLC Cassava Sciences Inc Put Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 13, 2025	BUY	$2.29 - $32.18 $19,465 - $273,530	8,500 Added 9.28%	100,100 $999 Million
Q3 2024 Nov 12, 2024	BUY	$9.57 - $35.08 $15,312 - $56,128	1,600 Added 1.78%	91,600 $488 Million
Q1 2024 May 13, 2024	BUY	$18.44 - $26.41 $1.66 Million - $2.38 Million	90,000 New	90,000 $266 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $233,688 - $370,944	8,400 Added 71.79%	20,100 $181,000
Q3 2022 Nov 14, 2022	SELL	$16.33 - $51.06 $60,420 - $188,922	-3,700 Reduced 24.03%	11,700 $73,000
Q2 2022 Aug 12, 2022	BUY	$17.22 - $38.47 $58,547 - $130,798	3,400 Added 28.33%	15,400 $159,000
Q1 2022 May 12, 2022	SELL	$32.6 - $53.05 $107,580 - $175,065	-3,300 Reduced 21.57%	12,000 $119,000
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $389,762 - $963,646	-10,600 Reduced 40.93%	15,300 $138,000
Q3 2021 Nov 10, 2021	BUY	$41.79 - $135.3 $559,986 - $1.81 Million	13,400 Added 107.2%	25,900 $167,000
Q2 2021 Aug 11, 2021	SELL	$32.15 - $89.72 $192,900 - $538,320	-6,000 Reduced 32.43%	12,500 $63,000
Q1 2021 May 14, 2021	BUY	$7.09 - $87.95 $131,165 - $1.63 Million	18,500 New	18,500 $93,000

131

14.2M

962K

864K

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $143M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.